Header Logo

Connection

Cristina Arriens to Lupus Erythematosus, Systemic

This is a "connection" page, showing publications Cristina Arriens has written about Lupus Erythematosus, Systemic.
  1. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Sci Med. 2020 04; 7(1).
    View in: PubMed
    Score: 0.408
  2. Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers. Lupus Sci Med. 2020; 7(1):e000360.
    View in: PubMed
    Score: 0.407
  3. Systemic lupus erythematosus biomarkers: the challenging quest. Rheumatology (Oxford). 2017 04 01; 56(suppl_1):i32-i45.
    View in: PubMed
    Score: 0.332
  4. Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus. Nutr J. 2015 Aug 18; 14:82.
    View in: PubMed
    Score: 0.296
  5. Neutrophils isolated from systemic lupus erythematosus patients exhibit a distinct functional phenotype. Front Immunol. 2024; 15:1339250.
    View in: PubMed
    Score: 0.134
  6. Ancestry-based differences in the immune phenotype are associated with lupus activity. JCI Insight. 2023 08 22; 8(16).
    View in: PubMed
    Score: 0.129
  7. Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE. Lupus Sci Med. 2023 07; 10(2).
    View in: PubMed
    Score: 0.128
  8. Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies. Front Immunol. 2021; 12:635072.
    View in: PubMed
    Score: 0.111
  9. Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020 12; 146(6):1419-1433.
    View in: PubMed
    Score: 0.103
  10. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 01; 72(1):78-88.
    View in: PubMed
    Score: 0.100
  11. Mock Recruitment for the Study of Antimalarials in an Incomplete Lupus Erythematosus Trial. Arthritis Care Res (Hoboken). 2019 11; 71(11):1425-1429.
    View in: PubMed
    Score: 0.099
  12. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. Trials. 2018 Dec 20; 19(1):694.
    View in: PubMed
    Score: 0.093
  13. Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study. J Proteome Res. 2016 07 01; 15(7):2102-14.
    View in: PubMed
    Score: 0.078
  14. Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE. Clin Immunol. 2016 08; 169:58-68.
    View in: PubMed
    Score: 0.078
  15. Resistin as a potential marker of renal disease in lupus nephritis. Clin Exp Immunol. 2015 Mar; 179(3):435-43.
    View in: PubMed
    Score: 0.072
  16. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 05 29; 397(10289):2070-2080.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.